Procoagulant Material From Human Urine in Prothrombin Activation

Mj, Caldwell; K, von Kaulla; Kaulla, von; Wh, Seegers

doi:10.1055/s-0038-1654960

Cited by 15 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54 It was later found that urinary PCA catalysed the conversion of prothrombin to thrombin only in the presence of platelet factor 3, factor V and Ca 2+ -a prothombinase type of activity, and was therefore classified as a 'platelet cofactor' rather than TF. 55,56 Aoki and von Kaulla further investigated the interaction between platelet factor 3, factor V, prothrombin, and urinary PCA. 57 They concluded that platelet factor 3 could be replaced by phospholipids in the activation of prothombin with partially purified urinary procoagulant (uPC), provided that the lipid was used under optimal conditions.…”

Section: Utf-a Historical Perspectivementioning

confidence: 99%

Urinary tissue factor: a potential marker of disease

Lwaleed¹,

Bass²,

Francis

1999

J. Pathol.

View full text Add to dashboard Cite

Tissue factor (TF) is the main physiological initiator of blood coagulation and may be important in the biology of a variety of solid malignancies, particularly where angiogenesis is a critical factor. TF is frequently encrypted in the plasma membrane of cells in contact with blood, and is exposed only after stimulation by certain agonists. Cancer cells variably express TF and cancer cell lines which exhibit multidrug resistance contain more TF than parental cells. TF is increased in both tumour‐associated macrophages and blood monocytes and has been implicated in abnormal coagulation activation seen in patients with inflammatory conditions and cancer. TF is also found in urine (uTF) in a lipid‐associated form, probably of kidney origin. uTF levels can be assayed in a cost‐effective manner and may be clinically important, particularly in patients with renal disorders and malignancy. uTF levels are not significantly affected by age, gender or cigarette smoking. Copyright © 1999 John Wiley & Sons, Ltd.

show abstract

Section: Utf-a Historical Perspectivementioning

confidence: 99%

Urinary tissue factor: a potential marker of disease

Lwaleed¹,

Bass²,

Francis

1999

J. Pathol.

View full text Add to dashboard Cite

show abstract

“…The mean platelet count after the injection (268.4 ± 85.5 thousands/mm 3 ) was lower than the mean platelet count before the injection (279.6 ± 86.0 thousands/ mm 3 ) . This fall in the mean platelet count is significant (t = 2.575, 0 .02<p < 0.05) ( Table 7).…”

Section: Effect Of Urokinase Injection On Platelet Aggregationmentioning

confidence: 64%

Studies with a Preparation of Urokinase

Dubber¹,

McNicol²,

Wilson³

et al. 1967

Thromb Haemost

View full text Add to dashboard Cite

SummaryThe evidence presented in this paper shows that though less coagulative than urokinase (Leo), urokinase (Abbott), both in vitro and in vivo, has coagulant activity. Further, evidence has been presented that urokinase may accelerate platelet aggregation. While it is likely that the intense fibrinolytic activity which may be produced by intravenous administration of urokinase would largely cancel out the coagulative activity in vivo, these properties in theory could predispose to thrombosis or perhaps more particularly to rethrombosis during therapy with urokinase and it would clearly be desirable, if possible, to obtain a preparation free from such coagulative properties.

show abstract

“…This includes autoprothrombin II and platelet cofactor I (F-VIII) (26). Furthermore, a fraction from urine serves as a platelet cofactor (28) . The urine component is, however, distinguished from the others by its independently strong procoagulant activity (29).…”

Section: Discussionmentioning

confidence: 99%

Blood Coagulation

Seegers¹,

Grammens²,

McCoy³

1970

Thromb Haemost

View full text Add to dashboard Cite

SummaryPreparations of platelet factor 3 accelerated the conversion of purified autoprothrombin III (F-X) to autoprothrombin C (F-X?). The reaction was slow and the yields were low. Purified Hageman factor or purified autoprothrombin II (F-IX?) functioned as platelet cofactors. Each increased the yield of autoprothrombin C from purified autoprothrombin III above that obtained with platelet factor 3 alone. Hageman protein thus has a role in the direct acceleration of the first basic reaction in blood coagulation. Purified prothrombin was made refractory to the two-stage analytical reagents with Hageman factor.

show abstract

Procoagulant Material From Human Urine in Prothrombin Activation

Cited by 15 publications

References 4 publications

Urinary tissue factor: a potential marker of disease

Urinary tissue factor: a potential marker of disease

Studies with a Preparation of Urokinase

Blood Coagulation

Contact Info

Product

Resources

About